AIEQ250117C36000
- 0.00
- 0.000.00%
AI Powered Equity ETF Newsroom
'HCLTech and Microsoft Expand Partnership to Revolutionise Contact Centers With Generative AI' - CNBC
'Google Cloud Forms New AI Sales Team, Cuts 60 Jobs' - The Information
Microsoft has formed a new AI team aimed at end-to-end application development and deployment.
① Microsoft announced the establishment of a new department called "Core AI Platform and Tools," led by Jay Parikh, focused on AI application development and third-party tool provision; ② The newly formed team will bring together experts from various fields to concentrate efforts on the research and development of AI platforms, tools, and infrastructure.
Looking up to 800 dollars! Morgan Stanley raises the target price for Tesla, with the most optimistic expectation doubling the increase.
Morgan Stanley Analysts reaffirm that Tesla remains the "preferred choice" and have raised the Target Price by 7.5% to $430, emphasizing Tesla's autonomous driving technology and Asia Vets (EAI) as drivers of stock price potential, stating that Tesla's overall potential market scope will further expand, covering "many areas that are still not included in the company's buyer or seller financial models."
BofA Sees 'Surprising' Broadening of Rally in Semis to Start 2025
Stocks Edge Down Ahead Of Key Inflation Reports, Crude Hits 5-Month High, Bitcoin Sinks: What's Driving Markets Monday?
TikTok Ban Deadline Ahead: What Will Happen To App On Your Phone?
Apple, Samsung Lead Smartphone Shipments in 2024 but Chinese Rivals Gain Ground: IDC
Media: NVIDIA Blackwell chip racks have malfunctioned, leading major clients such as Microsoft to reduce some Orders.
① Reports indicate that the first batch of racks equipped with the Blackwell chip has experienced overheating issues, and there are also faults in the connection methods between the chips; ② It is reported that companies such as Microsoft, Amazon's cloud division, Google's parent company Alphabet, and Meta have reduced some Orders for the NVIDIA Blackwell GB200 racks.
Looking At Microsoft's Recent Unusual Options Activity
Tesla Is Valued at $2.5T in Morgan Stanley's Bull Case Scenario
Semi Industry Sales Forecast to Grow 12-14% in 2025: Wells Fargo
Arm Said to Hike Prices as Much as 300%, Consider Making Own Chips: Report
'EU Considers Expanding Probe Into Musk's X, Digital Chief Says' - Bloomberg News
Tesla Embodied AI, Robotaxi Dreams Propel Bullish Sentiment: Stock Chart Flashes Mixed Signals
10 Consumer Discretionary Stocks With Whale Alerts In Today's Session
10 Information Technology Stocks With Whale Alerts In Today's Session
PUBG Developer Krafton Invests $136 Million in Game Studios, Expands AI Team for Future Gaming Innovations
Live On CNBC, Rob Sechan Announces Bought NRG Energy; Bought Amazon
The anti-obesity drug battle escalates! The CEO of Eli Lilly and Co reveals that the company's oral medication may be released early next year.
① Eli Lilly and Co's CEO David Ricks expects that its experimental oral weight-loss drug orforglipron will be approved as early as early 2026; ② The phase II trial data for orforglipron shows significant weight loss in participants, with clinical significance; ③ Although Eli Lilly and Co is once again trailing Novo-Nordisk A/S, its weight-loss injectable has completely surpassed semaglutide in head-to-head studies.